Idarubicin
- Generic Name
- Idarubicin
- Brand Names
- Idamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27NO9
- CAS Number
- 58957-92-9
- Unique Ingredient Identifier
- ZRP63D75JW
- Background
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
- Indication
For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
- Associated Conditions
- Acute Myeloid Leukemia
BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia
- Conditions
- Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic TherapySecondary Acute Myeloid Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: Hematopoietic Cell TransplantationProcedure: Multigated Acquisition ScanProcedure: Punch Biopsy
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT04214249
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸Wake Forest Baptist Health - Wilkes Medical Center, Wilkesboro, North Carolina, United States
Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia
- Conditions
- Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2019-12-09
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT04190550
- Locations
- 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2019-10-02
- Last Posted Date
- 2022-03-14
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 63
- Registration Number
- NCT04112589
- Locations
- 🇪🇸
Hospital General Universitario de Alicante, Alicante, Spain
🇪🇸Institut Català D'Oncologia-Hospital Germans Trias I Pujol, Badalona, Spain
🇪🇸Institut Català D'Oncologia-Hospital Duran I Reynals, Bellvitge, Spain
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 273
- Registration Number
- NCT04107727
- Locations
- 🇪🇸
Hospital Universitari i Politecnic La Fe, Valencia, Spain
🇪🇸Hospital Clínico Universitario de Valladolid, Valladolid, Spain
🇪🇸Hospital Universitario Miguel Servet, Zaragoza, Spain
Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients
- Conditions
- Induction ChemotherapyAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- The First Affiliated Hospital of Soochow University
- Target Recruit Count
- 162
- Registration Number
- NCT04087967
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
IA14 Induction in Young Acute Myeloid Leukemia
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2021-06-08
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT04069208
- Locations
- 🇨🇳
Xinxin Cao, Beijing, Beijing, China
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Conditions
- Recurrent Acute Biphenotypic LeukemiaAcute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaBlasts 20 Percent or More of Bone Marrow Nucleated CellsRefractory Acute Myeloid LeukemiaRefractory High Risk Myelodysplastic SyndromeHigh Risk Myelodysplastic SyndromeRecurrent High Risk Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2019-08-07
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT04047641
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Delta-Fly Pharma, Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT03926624
- Locations
- 🇺🇸
University of California, Irvine, California, United States
🇺🇸Decatur Memorial Hospital-Cancer Care Specialists of Central IL, Decatur, Illinois, United States
🇺🇸The University of Mississippi Medical Center, Jackson, Mississippi, United States
Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
- Conditions
- Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 67
- Registration Number
- NCT03860844
- Locations
- 🇺🇸
Children's Medical Center of Dallas-Site Number:8400002, Dallas, Texas, United States
🇲🇽Investigational Site Number :4840001, Monterrey, Nuevo León, Mexico
🇧🇷Investigational Site Number :0760007, Porto Alegre, Rio Grande Do Sul, Brazil
Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol Emulsion
- First Posted Date
- 2018-11-01
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- University Hospital, Montpellier
- Target Recruit Count
- 53
- Registration Number
- NCT03727633
- Locations
- 🇫🇷
CHU d'Angers, Angers, France
🇫🇷CHU de Dijon, Dijon, France
🇫🇷CHU de Nice, Nice, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.